Innovative HIV Prevention with Lenacapavir Facing Challenges in Uganda

Lake Victoria Coast HIV Trials
In Uganda’s Lake Victoria coast, Irene, a 22-year-old participant, has grown through a significant HIV clinical trial. Her involvement was encouraged by her uncle’s battle with HIV. The landscape may seem unremarkable, yet this area has been pivotal in shaping HIV care.

Advancements in HIV Prevention
Thanks to lenacapavir, a drug approved for pre-exposure prophylaxis (PrEP), Irene no longer fears acquiring HIV. PrEP, like lenacapavir, provides protection without the need for daily pills. This groundbreaking drug is administered as an injection, providing six months of protection.

The lenacapavir trials, PURPOSE 1 and 2, showed remarkable results. The effectiveness led to early cessation of the randomized phase, allowing broader access to participants initially receiving a placebo.

Trial Results and Challenges
The PURPOSE 1 trial involved nearly 4,200 women, with none acquiring HIV after receiving lenacapavir. Adherence rates were impressive, with over 96% receiving the drug timely. PURPOSE 2 included men and gender-diverse individuals, showing slightly lower adherence with one HIV acquisition.

Dr. Flavia Matovu Kiweewa’s team in Uganda has been instrumental in these trials. They work to overcome challenges in adhering to daily medication, making lenacapavir a promising alternative with infrequent dosing.

Rollout Issues and Criticism
Despite approval by the FDA, lenacapavir faced a rocky rollout, especially concerning distribution and pricing. Uganda initially received 20,000 doses, but distribution has been uneven. High-risk areas like Kalangala were excluded from initial plans, raising concerns about equitable access.

It’s a mixed response from public health, with some praising simultaneous introductions in varied economies, while others call for better distribution strategies and pricing alignment.

Local Healthcare Challenges
In Kasensero, budget constraints have reduced contract lengths and strained healthcare workers like Amiri Kabuye tasked with distributing lenacapavir amid limited supplies. Skepticism persists around long-term funding and sustained supply, affecting rollout certainty.

Asia Russell, Executive Director of Health Global Access Project, critiques the rollout strategy as exposing potential patients to HIV unnecessarily. The Ugandan Ministry of Health has not responded to inquiries about distribution concerns.

Generics and Pricing Strategies
Gilead Sciences, the company behind lenacapavir, has strategies to make the drug affordable by signing agreements for generic production expected by 2027. Currently priced at $28,000 for two doses, lenacapavir is more costly compared to oral PrEP.

The company has pledged to sell at no profit until generics are available. Gilead highlights commitment to expand access swiftly, focusing on collaborations with governments and global partners.

International Aid and Future Plans
Uganda’s challenges extend beyond lenacapavir supply; U.S. funding cuts have impacted HIV treatment programs significantly. Staffing reductions in HIV prevention services complicate effective distribution and administration of new treatments.

Efforts from the U.S. aim to increase access by promising millions of doses worldwide, yet supply remains mismatched to actual demand, as 20 million could benefit from the drug.

Oral PrEP and Continuing Challenges
Despite lenacapavir’s promise, oral PrEP remains crucial. However, recent aid cuts have led to declines in new oral PrEP initiations. As costs and logistical challenges persist, oral PrEP continues to be essential in HIV prevention.

Lenacapavir’s reduced dosing frequency offers hope for logistical and transport cost savings, especially in remote locations like Kalangala’s island communities.

The Way Forward
Efforts continue in Uganda to reinforce HIV prevention, with lenacapavir offering potential despite current obstacles. Health workers acknowledge the vital support needed to prevent HIV’s spread.

Irene’s story, along with many others, reflects the urgent need for comprehensive solutions in HIV prevention to maintain hope and ensure better health outcomes.